$SDZ (-0.76%) - Approval for Enzeevu
The generics manufacturer has received approval in the USA for the biosimilar Enzeevu. Enzeevu is an active ingredient for the treatment of neovascular age-related macular degeneration, which Sandoz hopes will lead to growth in the important US market. The copycat drug Enzeevu is based on the blockbuster Eylea from Regeneron.
GG
$SDZ (-0.76%) - Convincing quarterly figures from Sandoz
The generics manufacturer generated sales of $2.6 billion in the second quarter of 2024, which corresponds to an increase of 9% in constant currencies. In the first half of 2024, sales rose by 7% to $5.0 billion. The biosimilar business in particular grew by 29%. Based on the positive business performance, Sandoz has raised its full-year sales growth guidance to a mid to high single-digit range in constant currencies.
Own position:
38 shares at 27.60
Happy Investing
GG
The price target is $43.99 and the stock is covered by 13 analysts.
Buy
10
Hold
3
Sell
0
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
